DNX-2401 adenovirus: Difference between revisions
(Created page with " {{TreatmentInfo |drug_name=DNX-2401 adenovirus |category=Oncolytic virotherapy |book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse event...") |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| Line 3: | Line 3: | ||
{{TreatmentInfo | {{TreatmentInfo | ||
|drug_name=DNX-2401 adenovirus | |drug_name=DNX-2401 adenovirus | ||
| | |treatment_category=Oncolytic virotherapy | ||
|book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO | |book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO | ||
trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. | trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. | ||
Latest revision as of 10:46, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | DNX-2401 adenovirus |
| FDA Approval | Not specified |
| Used for | Not specified |
| Clinical Trial Phase | Not specified |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specified |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | Not rated |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
From Ben Williams Book: Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse events attributable to the virus being reported. 3 of 25 patients responded to the treatment with complete, durable responses of 42, 32, and 29 months so far. These three complete responders had vigorous immune responses, with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance for type-1 anti-tumor immune responses.Property "Has original text" (as page type) with input value "Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO</br>trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.</br>Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented</br>at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma</br>patients had been treated, with no adverse events attributable to the virus being reported.</br>3 of 25 patients responded to the treatment with complete, durable responses of 42, 32,</br>and 29 months so far. These three complete responders had vigorous immune responses,</br>with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance</br>for type-1 anti-tumor immune responses." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
